Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

Anna C. Pavlick, DO, discusses the mechanism of action of vusolimogene oderparepvec in patients with anti–PD-1–failed cutaneous melanoma.

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.